Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNA.
Remon J, Caramella C, Jovelet C, Lacroix L, Lawson A, Smalley S, Howarth K, Gale D, Green E, Plagnol V, Rosenfeld N, Planchard D, Bluthgen MV, Gazzah A, Pannet C, Nicotra C, Auclin E, Soria JC, Besse B. Remon J, et al. Among authors: jovelet c. Ann Oncol. 2017 Apr 1;28(4):784-790. doi: 10.1093/annonc/mdx017. Ann Oncol. 2017. PMID: 28104619 Free article. Clinical Trial.
Circulating Tumor DNA Analysis for Patients with Oncogene-Addicted NSCLC With Isolated Central Nervous System Progression.
Aldea M, Hendriks L, Mezquita L, Jovelet C, Planchard D, Auclin E, Remon J, Howarth K, Benitez JC, Gazzah A, Lavaud P, Naltet C, Lacroix L, de Kievit F, Morris C, Green E, Ngo-Camus M, Rouleau E, Massard C, Caramella C, Friboulet L, Besse B. Aldea M, et al. Among authors: jovelet c. J Thorac Oncol. 2020 Mar;15(3):383-391. doi: 10.1016/j.jtho.2019.11.024. Epub 2019 Dec 13. J Thorac Oncol. 2020. PMID: 31843682 Free article.
Outcomes in oncogenic-addicted advanced NSCLC patients with actionable mutations identified by liquid biopsy genomic profiling using a tagged amplicon-based NGS assay.
Remon J, Swalduz A, Planchard D, Ortiz-Cuaran S, Mezquita L, Lacroix L, Jovelet C, Rouleau E, Leonce C, De Kievit F, Morris C, Jones G, Mercier K, Howarth K, Green E, Pérol M, Saintigny P, Besse B. Remon J, et al. Among authors: jovelet c. PLoS One. 2020 Jun 11;15(6):e0234302. doi: 10.1371/journal.pone.0234302. eCollection 2020. PLoS One. 2020. PMID: 32525942 Free PMC article.
Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with BRAF-Mutant Metastatic Non-Small Cell Lung Cancer.
Ortiz-Cuaran S, Mezquita L, Swalduz A, Aldea M, Mazieres J, Leonce C, Jovelet C, Pradines A, Avrillon V, Chumbi Flores WR, Lacroix L, Loriot Y, Westeel V, Ngo-Camus M, Tissot C, Raynaud C, Gervais R, Brain E, Monnet I, Giroux Leprieur E, Caramella C, Mahier-Aït Oukhatar C, Hoog-Labouret N, de Kievit F, Howarth K, Morris C, Green E, Friboulet L, Chabaud S, Guichou JF, Perol M, Besse B, Blay JY, Saintigny P, Planchard D. Ortiz-Cuaran S, et al. Among authors: jovelet c. Clin Cancer Res. 2020 Dec 1;26(23):6242-6253. doi: 10.1158/1078-0432.CCR-20-1037. Epub 2020 Aug 28. Clin Cancer Res. 2020. PMID: 32859654
Real-World Utility of an Amplicon-Based Next-Generation Sequencing Liquid Biopsy for Broad Molecular Profiling in Patients With Advanced Non-Small-Cell Lung Cancer.
Remon J, Lacroix L, Jovelet C, Caramella C, Howarth K, Plagnol V, Rosenfeld N, Morris C, Mezquita L, Pannet C, Ngocamus M, Le Pechoux C, Adam J, Grecea AM, Planchard D, Vassal G, Benitez JC, Gazzah A, Green E, Soria JC, Besse B. Remon J, et al. Among authors: jovelet c. JCO Precis Oncol. 2019 Mar 6;3:PO.18.00211. doi: 10.1200/PO.18.00211. eCollection 2019. JCO Precis Oncol. 2019. PMID: 32914037 Free PMC article.
Clinical Relevance of an Amplicon-Based Liquid Biopsy for Detecting ALK and ROS1 Fusion and Resistance Mutations in Patients With Non-Small-Cell Lung Cancer.
Mezquita L, Swalduz A, Jovelet C, Ortiz-Cuaran S, Howarth K, Planchard D, Avrillon V, Recondo G, Marteau S, Benitez JC, De Kievit F, Plagnol V, Lacroix L, Odier L, Rouleau E, Fournel P, Caramella C, Tissot C, Adam J, Woodhouse S, Nicotra C, Auclin E, Remon J, Morris C, Green E, Massard C, Pérol M, Friboulet L, Besse B, Saintigny P. Mezquita L, et al. Among authors: jovelet c. JCO Precis Oncol. 2020 Apr 2;4:PO.19.00281. doi: 10.1200/PO.19.00281. eCollection 2020. JCO Precis Oncol. 2020. PMID: 32923908 Free PMC article.
Oncogenic Fusions May Be Frequently Present at Resistance of EGFR Tyrosine Kinase Inhibitors in Patients With NSCLC: A Brief Report.
Enrico D, Lacroix L, Chen J, Rouleau E, Scoazec JY, Loriot Y, Tselikas L, Jovelet C, Planchard D, Gazzah A, Mezquita L, Ngo-Camus M, Michiels S, Massard C, Recondo G, Facchinetti F, Remon J, Soria JC, André F, Vassal G, Friboulet L, Besse B. Enrico D, et al. Among authors: jovelet c. JTO Clin Res Rep. 2020 Mar 7;1(2):100023. doi: 10.1016/j.jtocrr.2020.100023. eCollection 2020 Jun. JTO Clin Res Rep. 2020. PMID: 34589930 Free PMC article.
Clinical Utility and Outcomes Impact of Crystal Digital PCR of Sensitizing and Resistance EGFR Mutations in Patients With Advanced Non-Small Cell Lung Cancer.
Riudavets M, Lamberts V, Vasseur D, Auclin E, Aldea M, Jovelet C, Naltet C, Lavaud P, Gazzah A, Aboubakar F, Dorta M, Remon J, Rouleau E, Ngocamus M, Nicotra C, Lacroix L, Besse B, Mezquita L, Planchard D. Riudavets M, et al. Among authors: jovelet c. Clin Lung Cancer. 2022 Sep;23(6):e377-e383. doi: 10.1016/j.cllc.2022.05.010. Epub 2022 May 11. Clin Lung Cancer. 2022. PMID: 35660356
23 results